Cutting the cost of drug development?
- 1 April 2004
- journal article
- review article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 3 (4) , 360-364
- https://doi.org/10.1038/nrd1347
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Hypothesis: A single clinical trial plus causal evidence of effectiveness is sufficient for drug approvalClinical Pharmacology & Therapeutics, 2003
- The price of innovation: new estimates of drug development costsJournal of Health Economics, 2003
- Randomized Trials or Observational Tribulations?New England Journal of Medicine, 2000
- Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research DesignsNew England Journal of Medicine, 2000
- Bayesian methods in health technology assessment: a review.Health Technology Assessment, 2000
- Statistics notes: Treatment allocation in controlled trials: why randomise?BMJ, 1999
- New active substances authorized in the United Kingdom between 1972 and 1994British Journal of Clinical Pharmacology, 1998
- For Debate: The statistical basis of public policy: a paradigm shift is overdueBMJ, 1996
- Returns to R&D on new drug introductions in the 1980sJournal of Health Economics, 1994
- Design Considerations for AIDS TrialsNew England Journal of Medicine, 1990